ATE427107T1 - Eine neue verwendung von deferiprone - Google Patents

Eine neue verwendung von deferiprone

Info

Publication number: ATE427107T1
Authority: AT; Austria
Prior art keywords: deferiprone; patient; new use; cardiac disease; induced cardiac
Prior art date: 2000-06-30

Application number

AT01949158T

Other languages

English (en)

Inventor

Michael Spino

Antonia Piga

Original Assignee

Apotex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2001-06-28

Publication date

2009-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4166629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427107(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-06-28 Application filed by Apotex Inc filed Critical Apotex Inc

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE427107T1 publication Critical patent/ATE427107T1/de

Links

TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 title abstract 2
229960003266 deferiprone Drugs 0.000 title abstract 2
208000020446 Cardiac disease Diseases 0.000 abstract 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
206010065973 Iron Overload Diseases 0.000 abstract 2
208000019622 heart disease Diseases 0.000 abstract 2
208000002903 Thalassemia Diseases 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01949158T 2000-06-30 2001-06-28 Eine neue verwendung von deferiprone ATE427107T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2313270A CA2313270C (en)	2000-06-30	2000-06-30	Use of deferiprone in treating and preventing iron-induced cardiac disease

Publications (1)

Publication Number	Publication Date
ATE427107T1 true ATE427107T1 (de)	2009-04-15

Family

ID=4166629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01949158T ATE427107T1 (de)	2000-06-30	2001-06-28	Eine neue verwendung von deferiprone

Country Status (16)

Country	Link
US (2)	US7049328B2 (de)
EP (1)	EP1294379B1 (de)
CN (3)	CN101380322B (de)
AT (1)	ATE427107T1 (de)
AU (2)	AU7040201A (de)
BR (1)	BR0112280A (de)
CA (1)	CA2313270C (de)
CY (1)	CY1109191T1 (de)
DE (1)	DE60138189D1 (de)
DK (1)	DK1294379T3 (de)
ES (1)	ES2324978T3 (de)
HK (1)	HK1043316A1 (de)
IL (2)	IL153733A0 (de)
PT (1)	PT1294379E (de)
WO (1)	WO2002002114A1 (de)
ZA (1)	ZA200109322B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007095728A1 (en) *	2006-02-22	2007-08-30	Arnold Munnich	The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CN101679263B (zh)	2007-03-28	2014-01-15	阿普泰克斯科技公司	去铁酮的氟化衍生物
EP2268282B1 (de) *	2008-04-25	2014-10-29	Apotex Technologies Inc.	Flüssige formulierung von deferipron mit angenehmem geschmack
GEP20146008B (en)	2009-07-03	2014-01-10	Apotex Tech Inc	Fluorinated derivatives of 3-hydroxypyridin-4-ones
US8603814B2 (en) *	2009-07-20	2013-12-10	Rutgers The State University Of New Jersey	Method of inhibiting nonsense-mediated mRNA decay
US9849146B2 (en)	2009-07-20	2017-12-26	Rutgers, The State University Of New Jersey	Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
AU2012327224A1 (en) *	2011-11-18	2013-06-06	Apotex Technologies Inc.	Methods of treatment with deferiprone
WO2016029158A2 (en) *	2014-08-21	2016-02-25	Collaborative Medicinal Development Llc	Compositions and methods for extending lifespan
KR20230004944A (ko) *	2016-08-05	2023-01-06	아브페로 파마슈티칼스, 인크.	금속-매개 상태를 치료하기 위한 투여 요법
CN106983746A (zh) *	2017-03-23	2017-07-28	武汉联合药业有限责任公司	一种药物组合物及其用途
MD3684344T2 (ro)	2017-10-25	2025-09-30	Chiesi Farm Spa	Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
EP3999059A1 (de) *	2019-07-19	2022-05-25	Vifor (International) Ag	Ferroportin-inhibitoren zur verwendung in der behandlung von transfusionsabhängiger beta-thalassämie (tdt)
CN114217071B (zh) *	2021-12-01	2023-11-14	柏荣诊断产品（上海）有限公司	一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒
AU2023253115A1 (en)	2022-04-11	2024-11-21	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
CN115429881A (zh) *	2022-09-02	2022-12-06	中国医学科学院基础医学研究所	铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2118176B (en) *	1982-03-24	1985-12-04	Nat Res Dev	Pharmaceutical compositions
US5922761A (en) *	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor

2000
- 2000-06-30 CA CA2313270A patent/CA2313270C/en not_active Expired - Fee Related
2001
- 2001-03-26 CN CN200810128993.5A patent/CN101380322B/zh not_active Expired - Lifetime
- 2001-03-26 CN CN2010102721482A patent/CN101933924A/zh active Pending
- 2001-03-26 CN CN01121242A patent/CN1331971A/zh active Pending
- 2001-06-28 BR BR0112280-0A patent/BR0112280A/pt not_active Application Discontinuation
- 2001-06-28 IL IL15373301A patent/IL153733A0/xx unknown
- 2001-06-28 AT AT01949158T patent/ATE427107T1/de active
- 2001-06-28 EP EP01949158A patent/EP1294379B1/de not_active Revoked
- 2001-06-28 US US10/311,814 patent/US7049328B2/en not_active Expired - Lifetime
- 2001-06-28 DE DE60138189T patent/DE60138189D1/de not_active Expired - Lifetime
- 2001-06-28 DK DK01949158T patent/DK1294379T3/da active
- 2001-06-28 WO PCT/CA2001/000956 patent/WO2002002114A1/en not_active Ceased
- 2001-06-28 AU AU7040201A patent/AU7040201A/xx active Pending
- 2001-06-28 PT PT01949158T patent/PT1294379E/pt unknown
- 2001-06-28 AU AU2001270402A patent/AU2001270402B9/en not_active Expired
- 2001-06-28 ES ES01949158T patent/ES2324978T3/es not_active Expired - Lifetime
- 2001-11-13 ZA ZA200109322A patent/ZA200109322B/xx unknown
2002
- 2002-07-08 HK HK02105057.7A patent/HK1043316A1/zh unknown
- 2002-12-29 IL IL153733A patent/IL153733A/en active IP Right Grant
2006
- 2006-01-13 US US11/331,101 patent/US20060122273A1/en not_active Abandoned
2009
- 2009-06-29 CY CY20091100679T patent/CY1109191T1/el unknown

Also Published As

Publication number	Publication date
ES2324978T3 (es)	2009-08-21
CN101933924A (zh)	2011-01-05
CY1109191T1 (el)	2014-07-02
IL153733A0 (en)	2003-07-06
CN101380322B (zh)	2015-06-24
DE60138189D1 (de)	2009-05-14
CN1331971A (zh)	2002-01-23
EP1294379A1 (de)	2003-03-26
WO2002002114A1 (en)	2002-01-10
US20060122273A1 (en)	2006-06-08
ZA200109322B (en)	2002-10-21
AU7040201A (en)	2002-01-14
US7049328B2 (en)	2006-05-23
CA2313270C (en)	2011-09-13
IL153733A (en)	2010-04-29
DK1294379T3 (da)	2009-06-02
EP1294379B1 (de)	2009-04-01
HK1130422A1 (en)	2009-12-31
CN101380322A (zh)	2009-03-11
PT1294379E (pt)	2009-05-04
US20030158234A1 (en)	2003-08-21
CA2313270A1 (en)	2001-12-30
AU2001270402B9 (en)	2006-03-02
BR0112280A (pt)	2003-05-13
HK1043316A1 (zh)	2002-09-13
AU2001270402B2 (en)	2006-02-02

Similar Documents

Publication	Publication Date	Title
CY1109191T1 (el)	2014-07-02	Μια νεα χρηση της δεφεριπρονης
CY1123084T1 (el)	2021-10-29	Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB0225474D0 (en)	2002-12-11	Therapeutic agents
GB0223038D0 (en)	2002-11-13	Therapeutic compounds
MXPA03006855A (es)	2004-03-12	Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
DK0665749T3 (da)	2000-08-28	Sammensætning til behandling af Parkinsons sygdom
ATE422357T1 (de)	2009-02-15	Verwendung von allopurinol zur behandlung von bluthochdruck
WO2001058476A3 (en)	2002-03-28	Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
SE0102147D0 (sv)	2001-06-18	New methods
WO2002059346A3 (en)	2003-07-31	Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
ATE313334T1 (de)	2006-01-15	Behandlung von tumoren mit photodynamischer therapie
EA200501549A1 (ru)	2006-04-28	Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
PT1237562E (pt)	2005-03-31	Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE297739T1 (de)	2005-07-15	Endothelin-antagonisten zur behandlung von herzversagen
ATE344662T1 (de)	2006-11-15	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE268170T1 (de)	2004-06-15	Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
EP1270000A3 (de)	2003-02-12	Benzoesäure-substituierte Benzopyrane zur Behandlung von Atherosklerose
DE602006020838D1 (de)	2011-05-05	Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
JP2002533400A5 (de)	2007-02-22
EE200100122A (et)	2002-06-17	R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
RU2000117402A (ru)	2003-07-10	Способ лечения микробной экземы
WO2004045505A3 (en)	2004-07-15	Extract of stephaniae sinica diels and methods of using the same
RU99122488A (ru)	2001-08-20	Способ лечения рака эндометрия
ATE312606T1 (de)	2005-12-15	Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock

Legal Events

Date

Code

Title

Description

2009-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1294379

Country of ref document: EP